Emerging Therapies for Refractory cGvHD: Potential Advantages of Axatilimab
The final segment explores the potential role of axatilimab, a novel agent, in the management of refractory cGvHD, highlighting its mechanism of action and potential efficacy compared to existing treatment options.
EP: 1.Diagnosis and Initial Management of cGVHD
EP: 2.Steroid-Refractory cGvHD: Emerging Treatment Options
EP: 3.Ruxolitinib and Ibrutinib for the Treatment of Chronic Graft-versus-Host Disease
EP: 4.Moderate cGvHD with Skin, Eye, and Oral Involvement
EP: 5.Emerging Therapies for Chronic Graft-Versus-Host Disease
EP: 6.Severe, Multi-Organ Chronic Graft-versus- Host Disease (cGvHD): Diagnosis and Initial Treatment Approach
EP: 7.Emerging Therapies for Refractory cGvHD: Potential Advantages of Axatilimab
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
